読み込み中
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
前日終値
$0.2799
−$0.005 · -1.75%
日中の時刻はETです。市場データは遅延する場合があります。
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
日中レンジ
現在 $0.2799
52週レンジ
現在 $0.2799
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
22
割高
センチメント
53
まちまち
リスク
50
やや高いリスク
モメンタム
29
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
日中レンジ
現在 $0.2799
52週レンジ
現在 $0.2799
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上高 | 118.6万 USD | 127.1万 USD | 134.5万 USD | 91.1万 USD | 39.7万 USD |
| 売上原価 | 83.4万 USD | 65.2万 USD | 61.2万 USD | 106.9万 USD | 20.3万 USD |
| 粗利益 | 35.2万 USD | 61.9万 USD | 73.3万 USD | −15.8万 USD | 19.4万 USD |
| 研究開発 | 519.3万 USD | 365.5万 USD | 377.3万 USD | 346.1万 USD | 233万 USD |
| 販売・一般管理 | 536.2万 USD | 441万 USD | 675.8万 USD | 795.2万 USD | 1329.2万 USD |
| 営業費用 | 1055.5万 USD | 806.5万 USD | 1053.1万 USD | 1141.3万 USD | 1562.2万 USD |
| 減価償却費と償却費 | 5.8万 USD | 61.8万 USD | 63.7万 USD | 65.7万 USD | 65.1万 USD |
| 営業利益 | −1020.3万 USD | −744.6万 USD | −979.8万 USD | −1157.1万 USD | −1542.8万 USD |
| 純利益 | −654.8万 USD | −712.1万 USD | −1300万 USD | −1150.6万 USD | −1501.6万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
